Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI-6129 in Advanced Solid Tumors
NCT05584709Phase 1Not yet recruiting
- Sponsor
- Sorrento Therapeutics
- Start
- Mar 2023
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of STI-6129 in solid tumor (advanced stage), sponsored by Sorrento Therapeutics. Primary endpoints: Incidence of adverse events by type, frequency, severity, and causality at 24 months, Incidence of serious adverse events by type, frequency, severity, and causality at 24 months and 3 more. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
STI-6129
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05584709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05584709.